Ladiratuzumab Vedotin is a monoclonal antibody conjugated commercialized by Merck, with a leading Phase II program in Esophageal Squamous Cell Carcinoma (ESCC). According to Globaldata, it is involved in 4 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Ladiratuzumab Vedotin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Ladiratuzumab Vedotin is expected to reach an annual total of $19 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Ladiratuzumab Vedotin Overview
Ladiratuzumab vedotin (SGN-LIV1A) is under development for the treatment of HR positive metastatic breast cancer, HER2 positive and negative metastatic breast cancer, LIV-1-positive metastatic triple negative breast cancer, small-cell lung cancer, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, head and neck cancer squamous cell carcinoma, esophageal squamous cell carcinoma gastric cancer, adenocarcinoma of the gastroesophageal junction, metastatic castration-resistant prostate cancer and malignant melanoma. It is administered through the intravenous route. The drug candidate is an antibody-drug conjugate which is comprised of an anti-LIV-1 monoclonal antibody linked to a synthetic cell-killing agent called monomethyl auristatin E (MMAE). The drug candidate is developed based on antibody-drug conjugate (ADC) technology. It was also under development for the treatment of cervical cancer.
Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
The company reported revenues of (US Dollars) US$59,283 million for the fiscal year ended December 2022 (FY2022), an increase of 21.7% over FY2021. The operating profit of the company was US$18,152 million in FY2022, compared to an operating profit of US$12,538 million in FY2021. The net profit of the company was US$14,519 million in FY2022, compared to a net profit of US$13,049 million in FY2021.
For a complete picture of Ladiratuzumab Vedotin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.